Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 90

Results For "Head"

1651 News Found

Polysciences announces new bioprocessing brand ‘Kyfora Bio’
News | January 03, 2023

Polysciences announces new bioprocessing brand ‘Kyfora Bio’

Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.


Mandaviya and Puri hail MoU between IndianOil and Central TB Division for states of UP and Chhattisgarh
Policy | December 29, 2022

Mandaviya and Puri hail MoU between IndianOil and Central TB Division for states of UP and Chhattisgarh

This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep


AIIMS organises consultation on ‘C2IQ’
News | December 29, 2022

AIIMS organises consultation on ‘C2IQ’

For anaemia control in children (0-19 years) & resolves for Call to Action in this direction


Mandaviya visits Safdarjung Hospital; Reviews mock drill for ensuring readiness for COVID-19 management
Healthcare | December 28, 2022

Mandaviya visits Safdarjung Hospital; Reviews mock drill for ensuring readiness for COVID-19 management

Mock drills are being conducted across the country to review the preparedness for management of COVID-19


Advent International to acquire a significant stake in Suven Pharmaceuticals
News | December 26, 2022

Advent International to acquire a significant stake in Suven Pharmaceuticals

Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.


Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes
News | December 22, 2022

Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes

This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation


Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer
Diagnostic Center | December 22, 2022

Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe


BeatO appoints Dr. Navneet Agrawal as Chief Clinical Officer
People | December 22, 2022

BeatO appoints Dr. Navneet Agrawal as Chief Clinical Officer

He has published more than 100 research papers in several prestigious national and international journals